These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 20092879)

  • 1. Overactive bladder is not only overactive but also hypersensitive.
    Lee SR; Kim HJ; Kim A; Kim JH
    Urology; 2010 May; 75(5):1053-9. PubMed ID: 20092879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of urodynamic filling sensation at weekly interval in healthy volunteers and in women with detrusor overactivity.
    Van Meel TD; Wyndaele JJ
    Neurourol Urodyn; 2011 Nov; 30(8):1586-90. PubMed ID: 21538500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence.
    Lin LY; Yeh NH; Lin CY; Sheu BC; Lin HH
    Urology; 2004 Nov; 64(5):945-9. PubMed ID: 15533483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.
    Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T
    Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
    Liu HT; Kuo HC
    Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
    Kuo HC; Liu HT; Chancellor MB
    Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.
    Chung SD; Liao CH; Chen YC; Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How sudden is a compelling desire to void? An observational cystometric study on the suddenness of this sensation.
    De Wachter S; Wyndaele JJ
    BJU Int; 2008 Apr; 101(8):1000-3. PubMed ID: 18218058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic findings in female diabetic patients with and without overactive bladder symptoms.
    Ho CH; Tai HC; Yu HJ
    Neurourol Urodyn; 2010 Mar; 29(3):424-7. PubMed ID: 19283863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence.
    Parsons M; Amundsen CL; Cardozo L; Vella M; Webster GD; Coats AC;
    Neurourol Urodyn; 2007; 26(6):800-6. PubMed ID: 17335054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining overactive bladder as hypersensitivity.
    Yamaguchi O; Honda K; Nomiya M; Shishido K; Kakizaki H; Tanaka H; Yamanishi T; Homma Y; Takeda M; Araki I; Obara K; Nishizawa O; Igawa Y; Goto M; Yokoyama O; Seki N; Takei M; Yoshida M
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):904-7. PubMed ID: 17663416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls.
    Cheng Y; Mansfield KJ; Allen W; Millard RJ; Burcher E; Moore KH
    Neurourol Urodyn; 2013 Sep; 32(7):969-73. PubMed ID: 23129360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder sensations during filling cystometry are different according to urodynamic diagnosis.
    Digesu GA; Basra R; Khullar V; Hendricken C; Camarata M; Kelleher C
    Neurourol Urodyn; 2009; 28(3):191-6. PubMed ID: 18973145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.
    Hashim H; Malmberg L; Graugaard-Jensen C; Abrams P
    Neurourol Urodyn; 2009; 28(1):40-6. PubMed ID: 18726947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does adenosine triphosphate released into voided urodynamic fluid contribute to urgency signaling in women with bladder dysfunction?
    Cheng Y; Mansfield KJ; Allen W; Walsh CA; Burcher E; Moore KH
    J Urol; 2010 Mar; 183(3):1082-6. PubMed ID: 20092837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of rectal distension on bladder function in patients with overactive bladder.
    Akl MN; Jacob K; Klauschie J; Crowell MD; Kho RM; Cornella JL
    Neurourol Urodyn; 2012 Apr; 31(4):541-3. PubMed ID: 22275153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.